- 関
- dalteparin
WordNet
- a silvery soft waxy metallic element of the alkali metal group; occurs abundantly in natural compounds (especially in salt water); burns with a yellow flame and reacts violently in water; occurs in sea water and in the mineral halite (rock salt) (同)Na, atomic number 11
PrepTutorEJDIC
- ソジウム,ナトリウム(金属元素;化学記号はNa)
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/12/12 13:07:25」(JST)
[Wiki en表示]
Dalteparin sodium
|
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
| Pregnancy cat. |
? |
| Legal status |
? |
| Identifiers |
| CAS number |
9041-08-1 |
| ATC code |
B01AB04 |
| DrugBank |
DB06779 |
| KEGG |
D03353 |
| Chemical data |
| Formula |
? |
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events.[1] Dalteparin is not superior to unfractionated heparin in preventing blood clots.[2]
Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.[3]
References[edit]
- ^ Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med 349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID 12853587.
- ^ The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011). Dalteparin versus unfractionated heparin in critically ill patients. doi:10.1056/NEJMoa1014475.
- ^ Douketis J, Cook D, Meade M et al. (2008). "Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin". Arch Intern Med 168 (16): 1805–1812. doi:10.1001/archinte.168.16.1805. PMID 18779469.
|
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
|
|
| Antiplatelet drugs |
|
Glycoprotein IIb/IIIa inhibitors
|
- Abciximab
- Eptifibatide
- Tirofiban
|
|
|
ADP receptor/P2Y12 inhibitors
|
- thienopyridines
- Clopidogrel
- Prasugrel
- Ticlopidine
- nucleotide/nucleoside analogs
- Cangrelor
- Elinogrel
- Ticagrelor
|
|
|
Prostaglandin analogue (PGI2)
|
- Beraprost
- Iloprost
- Prostacyclin
- Treprostinil
|
|
|
COX inhibitors
|
- Acetylsalicylic acid/Aspirin#
- Aloxiprin
- Carbasalate calcium
- Indobufen
- Triflusal
|
|
|
Thromboxane inhibitors
|
- thromboxane synthase inhibitors
- Dipyridamole (+Aspirin)
- Picotamide
- receptor antagonist
|
|
|
Phosphodiesterase inhibitors
|
- Cilostazol
- Dipyridamole
- Triflusal
|
|
|
Other
|
|
|
|
| Anticoagulants |
|
Vitamin K antagonists
(inhibit II, VII, IX, X)
|
- coumarins: Acenocoumarol
- Coumatetralyl
- Dicoumarol
- Ethyl biscoumacetate
- Phenprocoumon
- Warfarin#
- 1,3-Indandiones: Clorindione
- Diphenadione
- Phenindione
- other: Tioclomarol
|
|
|
Factor Xa inhibitors
(with some II inhibition)
|
Heparin group/
glycosaminoglycans/
(bind antithrombin) |
- low molecular weight heparin
- Bemiparin
- Certoparin
- Dalteparin
- Enoxaparin
- Nadroparin
- Parnaparin
- Reviparin
- Tinzaparin
- oligosaccharides
- heparinoid
- Danaparoid
- Dermatan sulfate
- Sulodexide
|
|
|
Direct Xa inhibitors
|
- xabans
- Apixaban
- Betrixaban
- Darexaban
- Edoxaban
- Otamixaban
- Rivaroxaban
|
|
|
|
Direct thrombin (II) inhibitors
|
- bivalent: Hirudin
- Bivalirudin
- Desirudin
- Lepirudin
- univalent: Argatroban
- Dabigatran
- Melagatran‡
- Ximelagatran‡
|
|
|
Other
|
- Antithrombin III
- Defibrotide
- Protein C
- Ramatroban
- REG1
|
|
|
Thrombolytic drugs/
fibrinolytics |
- plasminogen activators: r-tPA
- Alteplase
- Reteplase
- Tenecteplase
- UPA
- Anistreplase
- Monteplase
- Streptokinase#
- other serine endopeptidases: Ancrod
- Brinase
- Fibrinolysin
|
|
| Non-medicinal |
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
cell/phys (coag, heme, immu, gran), csfs
|
rbmg/mogr/tumr/hist, sysi/epon, btst
|
drug (B1/2/3+5+6), btst, trns
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency.
- Atiq F1, van den Bemt PM, Leebeek FW, van Gelder T, Versmissen J.
- European journal of clinical pharmacology.Eur J Clin Pharmacol.2015 Jun 14. [Epub ahead of print]
- PURPOSE: Although therapeutic dosages of most low-molecular-weight heparins (LMWHs) are known to accumulate in patients with renal insufficiency, for the lower prophylactic dosages this has not been clearly proven. Nevertheless, dose reduction is often recommended. We conducted a systematic review t
- PMID 26071276
- Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
- Francis CW1, Kessler CM2, Goldhaber SZ3, Kovacs MJ4, Monreal M5, Huisman MV6, Bergqvist D7, Turpie AG8, Ortel TL9, Spyropoulos AC1, Pabinger I10, Kakkar AK11.
- Journal of thrombosis and haemostasis : JTH.J Thromb Haemost.2015 Jun;13(6):1028-35. doi: 10.1111/jth.12923. Epub 2015 May 10.
- BACKGROUND: Treatment of venous thromboembolism (VTE) in patients with cancer has a high rate of recurrence and bleeding complications. Guidelines recommend low-molecular-weight heparin (LMWH) for at least 3-6 months and possibly indefinitely for patients with active malignancy. There are, however,
- PMID 25827941
- Randomized Controlled Trial to Evaluate Regional Citrate Anticoagulation Plus Low-Dose of Dalteparin in Continuous Veno-Venous Hemofiltration.
- Wu B1, Zhang K, Xu B, Ji D, Liu Z, Gong D.
- Blood purification.Blood Purif.2015 May 22;39(4):306-312. [Epub ahead of print]
- BACKGROUND/AIMS: To evaluate the efficacy and safety of regional citrate anticoagulation (RCA) plus low-dose dalteparin in patients receiving continuous veno-venous hemofiltration (CVVH).METHODS: Patients requiring pre-dilution CVVH at 4 l/h were randomly assigned to group A (RCA only), group B (nor
- PMID 26022434
Japanese Journal
- LDLアフェレシス(LDL-A)中にブラジキニン起因性ショックを起こしたと考えられたアンギオテンシンII type 1受容体拮抗薬服用中の1症例(<特集>急性臓器障害に対するアフェレシス)
- 永山 嘉恭,岩崎 滋樹,河嶋 英里,井上 嘉彦,由利 康裕,吉村 吾志夫
- 日本アフェレシス学会雑誌 26(3), 346-349, 2007-10-31
- … There were no anaphylactoid reactions and no complications during LDL-A therapies when we tried LDL-A using nafamostat mesilate (FUT) or dalteparin sodium (DA) instead of heparin. …
- NAID 110006404717
- Effect of low-molecular-weight heparin on the commitment of bone marrow cells to liver sinusoidal endothelial cells in CCl_4-induced liver injury
- SERIZAWA Nobuko,TAKEI Yoshiyuki,OKUBO Hironao,YAMASINA Shunhei,ENOMOTO Nobuyuki,SATO Nobuhiro
- Hepatology research : the official journal of the Japan Society of Hepatology 34(4), 207-213, 2006-04-01
- NAID 10020404845
Related Links
- Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism. The ...
- dalteparin sodium, a low-molecular-weight heparin. indications It is prescribed to prevent deep vein thrombosis in adults undergoing abdominal surgery who are at risk for clotting. It is also used for the treatment of unstable angina and ...
★リンクテーブル★
[★]
- 英
- dalteparin
- 化
- ダルテパリンナトリウム dalteparin sodium
- 商
- ダルテパリンNa、フラグミン、フレスバル、ヘパグミン、リザルミン
- 関
- 血液凝固阻止剤